Dipeptidyl peptidase-4 and kidney fibrosis in diabetes.
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes.
复制标题
DOI：
10.1186/s13069-016-0038-0
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Kanasaki K
中科院分区：
文献类型：
--
作者：
Shi S;Koya D;Kanasaki K
糖尿病肾病（DN）是全球终末期肾病最常见的原因，与1型和2型糖尿病患者的发病率和死亡率增加相关。最近的证据表明，二肽基肽酶-4（DPP-4）抑制剂可能对DN具有保护作用。事实上，肾脏是单位器官重量DPP-4活性水平最高的器官。一项临床前分析显示，DPP-4抑制剂也可改善肾纤维化。本文就DPP-4抑制剂的肾脏保护作用及其可能机制进行综述。
Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the DPP-4 activity is the highest level per organ weight. A preclinical analysis revealed that DPP-4 inhibitors also ameliorated kidney fibrosis. In this review, we analyzed recent reports in this field and explore the renoprotective effects and possible mechanism of the DPP-4 inhibitors.